Chronic Neutrophilic Leukemia: Current and Future Perspectives

Sangeetha Venugopal, John Mascarenhas

Research output: Contribution to journalReview articlepeer-review

7 Scopus citations

Abstract

Chronic neutrophilic leukemia (CNL) is a BCR-ABL1–negative myeloproliferative neoplasm with notably dismal survival. The current 2016 World Health Organization classification of myeloid neoplasms enables clinicians to unequivocally differentiate CNL from its comparable myelodysplastic/myeloproliferative neoplasm overlap syndromes. Additionally, the gradual emergence of next-generation sequencing has progressively expanded our evolving understanding of the molecular pathogenesis of CNL and its therapeutic potential. Hematopoietic stem-cell transplantation remains the primary therapeutic option for the effective treatment of CNL. In this comprehensive review, we highlight the contemporaneous classification, diagnostic criteria, and molecular pathogenesis of CNL. We also discuss the therapeutic implications of the heterogeneous molecular fingerprint of CNL, focusing on emerging targeted therapies, specifically inhibitors of JAK and MAPK signaling pathways.

Original languageEnglish
Pages (from-to)129-134
Number of pages6
JournalClinical Lymphoma, Myeloma and Leukemia
Volume19
Issue number3
DOIs
StatePublished - Mar 2019

Keywords

  • CSF3R
  • JAK-STAT
  • Myeloproliferative neoplasm
  • Ruxolitinib
  • SETBP1

Fingerprint

Dive into the research topics of 'Chronic Neutrophilic Leukemia: Current and Future Perspectives'. Together they form a unique fingerprint.

Cite this